Taysha Gene Therapies, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.

On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.

Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.

Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.